Hepatitis E: The New Challenges of a Peculiar Viral Hepatitis
HEV accounts for over three million clinical cases, 70,000 deaths, and 3,000 stillbirths, and 3.3% of all deaths from viral hepatitis worldwide. HEV infection mostly affects persons living in resource-limited settings with poor access to clean water and sanitation and can be particularly severe in pregnant women and neonates. In particular, HEV is a significant contributor to global maternal mortality, with reported case-fatality rates of 20–30%. In high-income countries, HEV represents a growing concern particularly in immunocompromised individuals and in patients with chronic liver disease, that are at high risk for the severe disease after HEV infection. Several diseases, including Guillain-Barré syndrome, neuralgic amyotrophy, glomerulonephritis, cryoglobulinemia, pancreatitis, lymphoma, thrombopenia, meningitis, thyroiditis and myocarditis have been observed in the setting of HEV infection presumably as a consequence of the direct cytopathic tissue damage by HEV replication, along with an overwhelming host immune response. There is limited availability and usage of diagnostic tools for the serologic and/or molecular diagnosis of hepatitis E infection, as well as a paucity of treatment options for severe disease, making effective outbreak response challenging. Learning objectives: Discuss virological and pathological aspects of HEV infection Describe epidemiological aspects of HEV infection How to diagnose and to follow-up patients for HEV infection Describe current and upcoming HEV treatment and prevention strategies Webinars will be available for unlimited on-demand viewing after live event.